ACADEMIC AND RESEARCH PEER-REVIEWED MEDICAL JOURNALISSN 1727-2378 (Print)         ISSN 2713-2994 (Online)
Ru
En

Anticoagulation Therapy: Gastroenterologists' Opinion

11 May 06:57

Objectives of the Review: To take a look at the use of anticoagulants in patients with comorbid disorders, to assess gastrointestinal (GI) tolerability of oral anticoagulants, and to identify the best therapeutic options for gastroprotection.

Key Points: The authors describe specific approaches to following up patients who have comorbid disorders and are taking anticoagulants. They also provide insight into drug interactions between anticoagulants and drugs that are used to treat GI diseases; and GI tolerability of anticoagulants. In addition, they provide information about periprocedural-management plans for patients with GI conditions, treatment strategies for bleeding in patients receiving anticoagulants, and the effects of food and diet. This paper also includes guidance on using anticoagulants in patients who have hypocoagulation caused by liver disorders.

Conclusion: Compared to warfarin, new oral anticoagulants (NOA) are associated with a lower rate of hemorrhagic events. New oral anticoagulants should not be used in patients with liver diseases that are associated with coagulation disorders and clinically significant risk of bleeding. When NOA need to be used in patients with comorbid disorders, proton-pump inhibitors, with minimal potential for drug-drug interactions, should be used to provide gastroprotection.

A. A. Masharova — S. I. Spasokukotsky City Clinical Hospital, Moscow Department of Healthcare. E-mail: a.masharova@gmail.com

Доктор.ру
11 May 06:57
LITERATURE
  1. Бордин Д. С. Новый подход к повышению эффективности ингибиторов протонной помпы у больного с гастроэзофагеальной рефлюксной болезнью // Лечащий врач. 2015. № 2. С. 47–51.
  2. Вёрткин А. Л., Наумов А. В. Деформирующий остеоартроз: стратегия ведения пациентов при соматической патологии // Рус. мед. журн. 2007. Т. 15. № 4. С. 319–328.
  3. Вовк Е. И., Фролова Ю. В., Вёрткин А. Л. Острые кровотечения из верхних отделов пищеварительного тракта у кардиологических больных // Лечащий врач. 2007. № 7. С. 70–72.
  4. Дьяков И. Н. Новые оральные антикоагулянты — место на отечественном фармацевтическом рынке // Ремедиум. 2014. № 11. С. 42–43.
  5. Лазебник Л. Б., Дроздов В. Н. Заболевания органов пищеварения у пожилых. М.: Анахарсис, 2003. 208 с.
  6. Подымова С. Д. Механизмы нарушений системы гемостаза у больных хроническими диффузными заболеваниями печени // Терапевт. арх. 1990. Т. 62. № 2. С. 72–76.
  7. Щекина Е. Г., Дроговоз С. М. Взаимодействие лекарств и пищи // Провизор. 2008. № 19. С. 34–38.
  8. Capodanno D., Capranzano P., Giacchi G., Calvi V. et al. Novel oral anticoagulants versus warfarin in non-valvular atrial fibrillation: a meta-analysis of 50,578 patients // Int. J. Cardiol. 2013. Vol. 167. N 4. P. 1237–1241.
  9. Connolly S. J., Ezekowitz M. D., Yusuf S., Eikelboom J. et al. RE-LY Steering Committee and Investigators Dabigatran versus warfarin in patients with atrial fibrillation // N. Engl. J. Med. 2009. Vol. 361. N 12. P. 1139–1151.
  10. Granger C. B., Alexander J. H., McMurray J. J., Lopes R. D. et al. Apixaban versus warfarin in patients with atrial fibrillation // N. Engl. J. Med. 2011. Vol. 365. N 11. P. 981–992.
  11. Heidbuchel H., Verhamme P., Alings M., Antz M. et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation // Europace. 2013. Vol. 15. N 5. P. 625–651.
  12. Horn J. The proton-pump inhibitors: similarities and differences // Clin. Ther. 2000. Vol. 22. N 3. P. 266–280.
  13. Lanza F. L. A guideline for the treatment and prevention of NSAID-induced ulcers. Members of the Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology // Am. J. Gastroenterol. 1998. Vol. 93. N 11. P. 2037–2046.
  14. Loffredo L., Perri L., Violi F. Impact of new oral anticoagulants on gastrointestinal bleeding in atrial fibrillation: a meta-analysis of interventional trials // Dig. Liver Dis. 2015. Vol. 47. N 5. P. 429–431.
  15. Patel M. R., Mahaffey K. W., Garg J., Pan G. et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation // N. Engl. J. Med. 2011. Vol. 365. N 10. P. 883–891.
  16. Scheppach W., Meesmann M. Exfoliative esophagitis while taking dabigatran // Dtsch Med. Wochenschr. 2015. Vol. 140. N 7. P. 515–518.
  17. Singh G., Triadafilopoulos G. Appropriate choice of proton pump inhibitor therapy in the prevention and management of NSAID-related gastrointestinal damage // Int. J. Clin. Pract. 2005. Vol. 59. N 10. P. 1210–1217.
Новости мировой медицины! Свежие статьи из журнала! Будьте в курсе!

Похожие статьи

Similar article
19 April 00:00, Interview
Interview
Doctor.Ru Pediatrics. Vol. 20, No. 3 (2021)
19 April 00:00, Paediatrics
A.V. Aksenov, E.A. Ivanovskaya
Successful Use of Tocilizumab in a Child with Systemic Juvenile Idiopathic Arthritis
Doctor.Ru Pediatrics. Vol. 20, No. 3 (2021)

News